Hematology Oncology Research

Publications

Researchers within the UCLA Division of Hematology-Oncology routinely disseminate the findings of their impactful work through publications in top-tier journals. Keep up with their latest articles here.

October 2026

  1. LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic A, Huppert L, Quintal L, Melisko M, Majure M, Chien J, Lechner M, Idossa D, Blaes A, McCann K, Rugo HS, Mortimer J. Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study. Breast. 2026 Sep 29;90:104941. doi: 10.1016/j.breast.2026.104941. Epub ahead of print. PMID: 42815081.
  2. Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark LN, Golmakani M, Jackson-Fisher A, Tang SY, Guo CC, Keliher EJ, Maresca K, Segal NH. A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers. Cancer Res Commun. 2026 Oct 1;6(10):2299-2310. doi: 10.1158/2767-9764.CRC-26-0101. PMID: 42696650; PMCID: PMC13629743.
  3. Maheswaran S, Dedeoglu AS, Niemierko A, Abelman RO, Jimenez R, Rieur O, Hutchinson J, Vidula N, Spring LM, Ellisen LW, Isakoff SJ, Wander SA, Bardia A, Medford AJ. Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability. Breast Cancer Res Treat. 2026 Sep 30;219(3):26. doi: 10.1007/s10549-026-08079-0. PMID: 42816667.
  4. Lin ME, Stenzel J, Delavary D, St John MA, Wong DJ, Ganz PA, Brauer ER. Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors of Head and Neck Cancer. Cancer Med. 2026 Oct;15(10):e72316. doi: 10.1002/cam4.72316. PMID: 42817585; PMCID: PMC13628158.
  5. Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang Y, Zhen A. Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model. Front Immunol. 2026 Sep 16;17:1856131. doi: 10.3389/fimmu.2026.1856131. PMID: 42818626; PMCID: PMC13623581.
  6. Ganz PA. Psychosocial burden in cancer survivors. Nat Rev Cancer. 2026 Oct 1. doi: 10.1038/s41568-026-00986-0. Epub ahead of print. PMID: 42823480.
  7. Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceu West R, Pillai PM, Marinello P, Timmerman JM. Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma. Blood Adv. 2026 Oct 2:bloodadvances.2025018506. doi: 10.1182/bloodadvances.2025018506. Epub ahead of print. PMID: 42826707.
  8. Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds J, Medd P, Searle E, Sochacki A, Savoie ML, Green S, Kato K, Hernandez R, Metenou S, Ma B, Pandite L, Schreiber TH, Sallman DA. Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. Cancer. 2026 Oct 1;132(19):e70626. doi: 10.1002/cncr.70626. PMID: 42829896; PMCID: PMC13634416.
  9. Olszewski AJ, Eradat HA, Avigdor A, Horowitz NA, McKinney MS, Lee ST, Bergua Burgues JM, Rodriguez Izquierdo A, Bastos-Oreiro M, Ganzel C, Kim TM, Jeon Y, Taszner M, Narkhede MS, Kim WS, Shin HJ, Woszczyk D, Goldschmidt N, Singh A, Wei MC, Wang J, Batlevi CL MD, PhD, Ead W, Janousek M, Sellam G Dr, Jurczak W. Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients. Blood. 2026 Oct 5:blood.2026035116. doi: 10.1182/blood.2026035116. Epub ahead of print. PMID: 42832423.
  10. O'Brien NA, Zhang J, Gong KW, McDermott MSJ, Hoffstrom B, Lu M, Liang M, Jia WP, Luo T, Madrid AM, Ayala R, Presta L, Larson SM, Glaspy JA, Slamon DJ. Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer. Clin Cancer Res. 2026 Oct 5. doi: 10.1158/1078-0432.CCR-26-2010. Epub ahead of print. PMID: 42832380.
  11. Carlson SG, Koo M, Dommaraju S, Song AH, Chai-Ho W. Rethinking the possibilities of adult ring sideroblastic anaemia. Lancet Haematol. 2026 Oct 6:S2352-3026(26)00133-X. doi: 10.1016/S2352-3026(26)00133-X. Epub ahead of print. PMID: 42838068.
  12. Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk M, Katanski CD, Bayat Tork AM, Zhang W, Nelson PS, Ha G, Haffner MC, Corey E, Morrissey C, Wang Y, Subramaniam AR, Lee JK, Ackerman SL, Pan T, Hsieh AC. tRNA dosage regulates lineage dependency and resistance in prostate cancer. Nature. 2026 Oct 7. doi: 10.1038/s41586-026-11153-8. Epub ahead of print. PMID: 42844465.
  13. Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis. J Med Econ. 2026 Dec;29(1):2423-2436. doi: 10.1080/13696998.2026.2733865. Epub 2026 Oct 7. PMID: 42839780.
  14. Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, Chawla S, Choy E, Davis LE, Gounder M, Haddadin S, Kasper B, Kim HS, Lee A, Lewin J, Hindi N, Mundi P, Ratan R, van der Graaf W, Yoon J, Birrenkott M, Fetterly G, Newhall K, Song E, Yovell J, Jones RL; RINGSIDE Phase II Study Investigators. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. J Clin Oncol. 2026 Oct 8:JCO2600725. doi: 10.1200/JCO-26-00725. Epub ahead of print. PMID: 42848980.
  15. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2026 Oct 9. doi: 10.1038/s43018-026-01268-2. Epub ahead of print. Erratum for: Nat Cancer. 2020;1(1):46-58. doi: 10.1038/s43018-019-0003-0. PMID: 42855593.
  16. Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Parmisano S, Brisbane W, Marks L, Singer AE, Rettig MB, Reiter RE, Valle LF, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. 177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial. Eur Urol. 2026 Oct 12:S0302-2838(26)02376-6. doi: 10.1016/j.eururo.2026.09.005. Epub ahead of print. PMID: 42864228.
  17. Ji J, Cohen HJ, Sedrak MS. Response to Zhang and Shi. J Natl Cancer Inst. 2026 Oct 12:djag380. doi: 10.1093/jnci/djag380. Epub ahead of print. PMID: 42861713.
  18. Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J, Chin Foo W, Boffo S, Arnott J, Dugan U, Subudhi SK, Sharma P. Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Sci Adv. 2026 Oct 16;12(42):eaee8730. doi: 10.1126/sciadv.aee8730. Epub 2026 Oct 14. PMID: 42873849; PMCID: PMC13666023.
  19. Nishimura RN, Gera JF. Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance. Int J Mol Sci. 2026 Sep 30;27(19):8743. doi: 10.3390/ijms27198743. PMID: 42883985.
  20. Saco JD, Karin D, Patten JJ, Bachl S, Ching C, Kale N, Fan Y, Medina E, Naser Al Deen N, Champhekar A, Kaelin WG, Schulman BA, Campbell KM, Carnevale J, Puig-Saus C, Ribas A. Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation. Cancer Immunol Res. 2026 Oct 15. doi: 10.1158/2326-6066.CIR-26-0181. Epub ahead of print. PMID: 42878659.
  21. Rocque G, Nipp R, Sedrak MS. Putting the Patient at the Center of Patient-Centered Care. JCO Oncol Pract. 2026 Oct 16:OP2600798. doi: 10.1200/OP-26-00798. Epub ahead of print. PMID: 42886890.
  22. Cai J, Sin D, Varda M, Lewis L, Yeh J. B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman. Clin Case Rep. 2026 Oct 17;14(10):e73736. doi: 10.1002/ccr3.73736. PMID: 42893054; PMCID: PMC13675837.
  23. Brown T, Lara MS, Jiang F, Garon EB, Goldman JW, Riess JW, Blakely CM. Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC. JTO Clin Res Rep. 2026 Aug 31;7(11):101072. doi: 10.1016/j.jtocrr.2026.101072. PMID: 42898856; PMCID: PMC13679293.
  24. Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, Chan SL, Edeline J, Klümpen HJ, Yau T, Verslype C, Ozaka M, Bouattour M, Park JO, Vogel A, Valle JW, Starkopf L, Malhotra U, Siegel AB, Qin S, Finn RS; KEYNOTE-966 Investigatorst; KEYNOTE-966 Investigators. Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial. EClinicalMedicine. 2026 Oct 12;100:104213. doi: 10.1016/j.eclinm.2026.104213. PMID: 42898854; PMCID: PMC13679299.
  25. Leshchiner I, Medford AJ, Cha J, Kiedrowski LA, Niemierko A, Keenan JC, Dai CS, Spring LM, Moy B, Wander SA, Vidula N, Isakoff SJ, Juric D, Miller M, Davis AA, Gerratana L, Shah A, Park BH, Brufsky A, O'Shaughnessy J, Nagy RJ, Ellisen LW, Cristofanilli M, Bardia A, Getz G. Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer. Nat Commun. 2026 Sep 22;17(1):11023. doi: 10.1038/s41467-026-75976-9. PMID: 42907427.
  26. O'Reilly EM, Wolpin BM, Wainberg ZA. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2026 Oct 22;395(16):1662. doi: 10.1056/NEJMc2611022. PMID: 42906097.
  27. Konecny GE, Lim PC, Santin AD, Gilbert L, Alvarez Secord A, Bessette P, Matulonis UA, Sen J, Hong J, Lytle GE, Bako E, Spunt SL, Provencher D, Madariaga A, Banerjee S, Eskander RN, Perez-Fidalgo JA, Roque D, Oaknin A. Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Clin Cancer Res. 2026 Oct 21. doi: 10.1158/1078-0432.CCR-26-0238. Epub ahead of print. PMID: 42905759.
  28. Margolis S, Kalbasi TR, Zektser Y, Niknafs A, Cui J, Lipsyc-Sharf MD, LeVee AA, Rugo HS, Bardia A, Sedrak MS. Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst. 2026 Oct 23:djag399. doi: 10.1093/jnci/djag399. Epub ahead of print. PMID: 42920260.
  29. George B, Singh H, Devoe CE, Chung V, Hosein PJ, Hendifar A, Kim DW, Valerin JB, Bekaii-Saab T, Cardin DB, Hidalgo M, Kasi PM, Leal AD, Pelster M, Fei N, Weekes CD, O'Hara MH, George TJ, Kazmi SM, Mizrahi JD, Nair S, Maiers M, Kheoh T, Amato G, Xavier J, Snyder JP, Milaszewski MH, Cabana-Puig X, Perry JR, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, Wainberg ZA, O'Reilly EM. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nat Med. 2026 Oct 23. doi: 10.1038/s41591-026-04734-7. Epub ahead of print. PMID: 42919966.
  30. Park D, Wu HT, Castillo DR, Mahuron K, Amini A, Patel K, Modi B, Salgia R, Wang EW, Trisal V, Guo M, Wu SP, Xing Y. Treatment Trends and Survival Outcomes in Clinical Stage III Melanoma: Real-World Analysis of NCDB Data. Target Oncol. 2026 Oct 22. doi: 10.1007/s11523-026-01265-6. Epub ahead of print. PMID: 42918959.
  31. Slamon DJ, Hortobagyi GN, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz SA, Barrios CH, Fernández AC, Untch M, Visco F, Perez AL, Miller M, Majumdar S, Peyrard S, Taran T, Fasching PA. Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial. Ann Oncol. 2026 Oct 23:S0923-7534(26)08640-0. doi: 10.1016/j.annonc.2026.10.1288. Epub ahead of print. PMID: 42918423.
  32. Goldman JW, Riess JW, Cho BC, Goldberg SB, Le X, Piotrowska Z, Okamoto I, Yu HA, García-Campelo R, de Castro Carpeño J, Ekman S, Reguart N, Paats MS, Kim SW, Kim YJ, Nishio M, Marrone KA, Smeland KB, Hendriks LEL, Akamatsu H, Shimizu J, Smith PE, Tang KH, Lehman JM, de Langen AJ. Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD. Clin Lung Cancer. 2026 Sep 5;27(9):52-61. doi: 10.1016/j.cllc.2026.09.001. Epub ahead of print. PMID: 42913244.
  33. Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle M, Macarulla T, Yopp A, Vogel A, Ohtsuka M, Ebata T, El-Meteini M, Abdelghafar MF, O'Kane G, El-Gendi A, Meyer T, Hong SK, Bhangui P, Finn R, Chan ACY, Mazzaferro V, Kim DS, Zhou J, Dong J, Hibi T, Wu H, Sapisochin G, Chieh Kow AW. Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology. Liver Cancer. 2026 Sep 5. doi: 10.1159/lic/admag012. Epub ahead of print. PMID: 42910203; PMCID: PMC13685653.
  34. Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review. Cureus. 2026 Sep 21;18(9):e116677. doi: 10.7759/cureus.116677. PMID: 42923345; PMCID: PMC13688280.
  35. Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M, Weber PY, Verzoni E, Porta C, Drakaki A, Guo J, Matsubara N, Chen A, Burgents JE, Rodriguez-Lopez KG, Powles TB. Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. Ann Oncol. 2026 Oct 25:S0923-7534(26)08071-3. doi: 10.1016/j.annonc.2026.10.1281. Epub ahead of print. PMID: 42927856.
  36. Powles T, Grande E, Simone G, Gómez de Liaño A, Maruzzo M, Velho PI, Kikuchi E, Vu TQ, Popovic L, Çil T, Gravis G, Radkowski R, Hernández LRN, Cutuli HJ, Bamias A, Bauernhofer T, Pavic M, Choi YJ, Chang CH, Kitamura H, Rosenberg JE, Rowbottom J, Ho S, Gupta A, Drakaki A; VOLGA Investigators. Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2608323. Epub ahead of print. PMID: 42929692.
  37. Zhang J, Murray J, Mu W, Venugopal S, Yim E, Einhaus T, Radtke S, Peterson CW, Kiem HP, An DS. Evaluation of Anti-HIV-1 HSPC-Based Gene Therapy with Negative Selection Marker in Pigtail Macaques. Viruses. 2026 Oct 13;18(10):1133. doi: 10.3390/v18101133. PMID: 42944053; PMCID: PMC13709364.
  38. Huynh K, Olevsky O, Mok T. Venous Thromboembolism in Pregnancy. Obstet Gynecol Clin North Am. 2026 Dec;53(4):723-746. doi: 10.1016/j.ogc.2026.07.001. Epub 2026 Sep 16. PMID: 42951441.
  39. Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang R, Petruse A, Yiqun J, Liran O. Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study. J Geriatr Oncol. 2026 Oct 28;18(2):104662. doi: 10.1016/j.jgo.2026.104662. Epub ahead of print. PMID: 42950609.
  40. McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios K, Sachdev JC, Wilner KD, Cole GW Jr, Kwei L, Beaupre DM, Orloff M. Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study. J Clin Oncol. 2026 Oct 28:JCO2600802. doi: 10.1200/JCO-26-00802. Epub ahead of print. PMID: 42950186.
  41. Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors. JCO Oncol Adv. 2026 Jan;3(4):e2600063. doi: 10.1200/oa-26-00063. Epub 2026 Oct 20. PMID: 42948761; PMCID: PMC13712313.
  42. Boix de Jesus A, Dao HB, Imani A, Rodriguez GA, Shehata MS, Chandran RR, Fine SA, Lim SY, To M, Lofftus SY, Pedroncelli N, Eilber FC, Gomperts BN, McCaw TR, Puig-Saus C, Crompton JG. p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells. Front Immunol. 2026 Oct 16;17:1910235. doi: 10.3389/fimmu.2026.1910235. PMID: 42964330; PMCID: PMC13719607.
  43. Moghanaki D, Goldman J, Weingrow D, Hendey GW. Discussing lung cancer management options in the emergency department. Emerg Med J. 2026 Oct 30:emermed-2026-216560. doi: 10.1136/emermed-2026-216560. Epub ahead of print. PMID: 42963123.
View the full list of Hematology Oncology publications